Dyne Therapeutics (DYN) Projected to Post Earnings on Thursday

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) is expected to be releasing its Q1 2025 earnings data before the market opens on Thursday, May 1st. Analysts expect Dyne Therapeutics to post earnings of ($0.88) per share for the quarter.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, topping analysts' consensus estimates of ($0.92) by $0.04. On average, analysts expect Dyne Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Dyne Therapeutics Stock Up 2.8 %

Shares of NASDAQ:DYN traded up $0.32 during midday trading on Tuesday, hitting $11.60. The stock had a trading volume of 228,384 shares, compared to its average volume of 1,531,534. The company has a market cap of $1.32 billion, a P/E ratio of -3.26 and a beta of 1.21. Dyne Therapeutics has a 12 month low of $6.36 and a 12 month high of $47.45. The business's 50-day simple moving average is $10.74 and its 200-day simple moving average is $19.38.

Insiders Place Their Bets

In other news, insider Oxana Beskrovnaya sold 2,598 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the sale, the insider now owns 199,087 shares of the company's stock, valued at $2,777,263.65. This trade represents a 1.29 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders have sold 6,237 shares of company stock valued at $77,760 in the last ninety days. 20.77% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts recently commented on DYN shares. Chardan Capital reiterated a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a report on Monday, March 17th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $45.00 price target on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Guggenheim reissued a "buy" rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. Scotiabank started coverage on shares of Dyne Therapeutics in a report on Friday, March 7th. They set a "sector outperform" rating and a $50.00 target price for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $46.00 price target on shares of Dyne Therapeutics in a report on Monday, March 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $47.46.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.